Refractory Kawasaki Disease—a Challenge for the Pediatrician

被引:8
|
作者
Deepu Abraham
Sridhar Kalyanasundaram
Kandamaran Krishnamurthy
机构
[1] Zulekha Hospital,
[2] Al Zahra Hospital,undefined
[3] Queen Elizabeth Hospital,undefined
关键词
Kawasaki disease; Atypical Kawasaki disease; Coronary dilation; IV immunoglobulin; Refractory Kawasaki disease; Coronary artery aneurysms; Intravenous immunoglobulin; Steroids; Infliximab; Plasma exchange;
D O I
10.1007/s42399-021-00775-w
中图分类号
学科分类号
摘要
Kawasaki disease (KD) is an acute, self-limiting febrile illness of childhood associated with vasculitis, mainly of the medium-sized arteries. The clinical significance and impact of this condition arise from its predilection for the coronary arteries. The criteria for classic Kawasaki disease are clearly defined, but many children present with atypical forms, and clinicians need to consider this possibility. Although most diagnosed cases respond to intravenous immunoglobulin (IVIG) and aspirin, some have proven resistant to the standard treatment. This article aims to provide a brief overview of Kawasaki disease, focusing on the resistant/refractory cases, and the treatment options available for such cases.
引用
收藏
页码:855 / 860
页数:5
相关论文
共 50 条
  • [41] Infliximab as a novel therapy for refractory Kawasaki disease (KD).
    Weiss, JE
    Eberhard, BA
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S310 - S310
  • [42] A Case of Hemophagocytic Lymphohistiocytosis following Refractory Kawasaki Disease
    Li, Ye
    Wang, Yulong
    Li, Shen
    Liu, Mingjing
    Wang, Dingding
    Xu, Chaoyue
    Zhang, Luan
    KLINISCHE PADIATRIE, 2020, 232 (02): : 73 - 76
  • [43] Kawasaki Disease Masquerading as Hepatitis: A Diagnostic Challenge for Pediatricians
    Majumdar, Indrajit
    Wagner, Sheri
    CLINICAL PEDIATRICS, 2016, 55 (01) : 73 - 75
  • [44] Re-treatment and risk factors of refractory Kawasaki disease
    Du, Zhong-Dong
    Zhao, Di
    Du, Junbao
    PEDIATRICS, 2008, 121 : S161 - S161
  • [45] Efficacy Of Plasma Exchange For Refractory Kawasaki Disease: The Earlier, The Better
    Hashimoto, Kunio
    Motomura, Hideki
    Moriuchi, Hiroyuki
    CIRCULATION, 2015, 131
  • [46] The Efficacy and Safety of Infliximab Therapy for Refractory Kawasaki Disease in Infants
    Furuta, Takashi
    Yasudo, Hiroki
    Ohnishi, Yuji
    Miyake, Akiko
    Okada, Seigo
    Suzuki, Yasuo
    Ohga, Shouichi
    Hasegawa, Shunji
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2020, 39 (08) : E219 - E219
  • [47] Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease
    Jibiki, Toshiaki
    Kato, Izumi
    Shiohama, Tadashi
    Abe, Katsuaki
    Anzai, Satoshi
    Takeda, Nobue
    Yamaguchi, Ken-ichi
    Kanazawa, Masaki
    Kurosaki, Tomomichi
    PEDIATRICS INTERNATIONAL, 2011, 53 (05) : 729 - 735
  • [48] An Interesting Case of Refractory Kawasaki Disease With Co-infection
    Kumar, Ratan
    Mishra, Adyasha
    Diwakar, Kumar
    Tanti, Sanjay K.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
  • [49] Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan
    Masuda, Hiroshi
    Kobayashi, Tohru
    Hachiya, Akira
    Nakashima, Yasutaka
    Shimizu, Hiroyuki
    Nozawa, Tomo
    Ogihara, Yoshihito
    Ito, Shuichi
    Takatsuki, Shinichi
    Katsumata, Nobuyuki
    Suzuki, Yasuo
    Takenaka, Satoshi
    Hirono, Keiichi
    Kobayashi, Tomio
    Suzuki, Hiroshi
    Suganuma, Eisuke
    Takahashi, Kei
    Saji, Tsutomu
    JOURNAL OF PEDIATRICS, 2018, 195 : 115 - +
  • [50] Kawasaki disease in newborns and infants:: refractory forms to immunoglobulin therapy
    Lucron, H
    Bosser, G
    Lethor, JP
    Sommelet, D
    Feillet, F
    Burger, G
    Monin, P
    Marçon, F
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 2004, 97 (05): : 522 - 528